Czapinski 1997a

Methods	36‐month randomised comparative trial Parallel study design Study conducted in Poland Method of generation of random list and allocation concealment not stated
Participants	Adults with newly diagnosed epilepsy Number randomised: PHT = 30; SV = 30 100% partial epilepsy, age range: 18 to 40 years Percentage men and range of follow‐up not mentioned
Interventions	Monotherapy with PHT or SV Starting doses: PHT: 200 mg/day, SV: 600 mg/day. Dose achieved not stated
Outcomes	Proportion achieving 24‐month remission at 3 years Exclusions after randomisation due to adverse events or no efficacy
Notes	Abstract only. Outcomes chosen for this review were not reported. IPD pledged but not received
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Trial "randomised" but no further information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"Exclusion rates" (interpreted as withdrawal rates) reported for all treatment groups, no further information provided
Selective reporting (reporting bias)	Unclear risk	No protocol available and trial reported only in abstract form, outcomes for this review not available
Other bias	Unclear risk	Insufficient detail provided in abstract to allow judgement